Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection

Pallavi R. Manuri, Bharti Nehete, Pramod N. Nehete, Rose Reisenauer, Seth Wardell, Amy N. Courtney, Ratish Gambhira, Dakshyani Lomada, Ashok Chopra, K. Jagannadha Sastry

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The E6 and E7 oncoproteins of the high-risk HPV type16 represent ideal targets for HPV vaccine development, they being consistently expressed in cervical cancer lesions. Since HPV-16 is primarily transmitted through genital mucosal route, mucosal immune responses constitute an essential feature for vaccination strategies against HPV-associated lesions. We present here evidence showing that mucosal immunization of mice by the intranasal route with a mixture of peptides E744-62 and E643-57 from the E7 and E6 oncoproteins of HPV-16, respectively, using a mutant cholera toxin adjuvant (CT-2*), primed strong antigen-specific cellular immune responses in systemic and mucosal tissues. Significant levels of IFN-γ production by both CD4 and CD8 cells were observed along with CTL responses that were effective against both peptide-pulsed targets as well as syngeneic tumor cells (TC-1) expressing the cognate E6 and E7 proteins. Furthermore, mice immunized with the peptide mixture and CT-2* effectively resisted TC-1 tumor challenge. These results together with our earlier observations that T cell responses to these peptides correlate with recurrence-free survival in women after ablative treatment for HPV-associated cervical intraepithelial neoplasia, support the potential of these E6 and E7 peptides for inclusion in vaccine formulations.

Original languageEnglish (US)
Pages (from-to)3302-3310
Number of pages9
JournalVaccine
Volume25
Issue number17
DOIs
StatePublished - Apr 30 2007

Fingerprint

Mucosal Immunity
Human papillomavirus 16
Papillomaviridae
synthetic peptides
Oncogene Proteins
Cellular Immunity
cell-mediated immunity
Immunization
immunization
peptides
Peptides
neoplasms
Neoplasms
lesions (animal)
mucosal immunity
Papillomavirus Vaccines
Cervical Intraepithelial Neoplasia
cholera toxin
uterine cervical neoplasms
Cholera Toxin

Keywords

  • HPV16 E7 and E6 peptides
  • Mucosal immunization
  • Mutant cholera toxin

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. / Manuri, Pallavi R.; Nehete, Bharti; Nehete, Pramod N.; Reisenauer, Rose; Wardell, Seth; Courtney, Amy N.; Gambhira, Ratish; Lomada, Dakshyani; Chopra, Ashok; Jagannadha Sastry, K.

In: Vaccine, Vol. 25, No. 17, 30.04.2007, p. 3302-3310.

Research output: Contribution to journalArticle

Manuri, Pallavi R. ; Nehete, Bharti ; Nehete, Pramod N. ; Reisenauer, Rose ; Wardell, Seth ; Courtney, Amy N. ; Gambhira, Ratish ; Lomada, Dakshyani ; Chopra, Ashok ; Jagannadha Sastry, K. / Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. In: Vaccine. 2007 ; Vol. 25, No. 17. pp. 3302-3310.
@article{06f1e18731fb4e1cbefed27bf0f56244,
title = "Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection",
abstract = "The E6 and E7 oncoproteins of the high-risk HPV type16 represent ideal targets for HPV vaccine development, they being consistently expressed in cervical cancer lesions. Since HPV-16 is primarily transmitted through genital mucosal route, mucosal immune responses constitute an essential feature for vaccination strategies against HPV-associated lesions. We present here evidence showing that mucosal immunization of mice by the intranasal route with a mixture of peptides E744-62 and E643-57 from the E7 and E6 oncoproteins of HPV-16, respectively, using a mutant cholera toxin adjuvant (CT-2*), primed strong antigen-specific cellular immune responses in systemic and mucosal tissues. Significant levels of IFN-γ production by both CD4 and CD8 cells were observed along with CTL responses that were effective against both peptide-pulsed targets as well as syngeneic tumor cells (TC-1) expressing the cognate E6 and E7 proteins. Furthermore, mice immunized with the peptide mixture and CT-2* effectively resisted TC-1 tumor challenge. These results together with our earlier observations that T cell responses to these peptides correlate with recurrence-free survival in women after ablative treatment for HPV-associated cervical intraepithelial neoplasia, support the potential of these E6 and E7 peptides for inclusion in vaccine formulations.",
keywords = "HPV16 E7 and E6 peptides, Mucosal immunization, Mutant cholera toxin",
author = "Manuri, {Pallavi R.} and Bharti Nehete and Nehete, {Pramod N.} and Rose Reisenauer and Seth Wardell and Courtney, {Amy N.} and Ratish Gambhira and Dakshyani Lomada and Ashok Chopra and {Jagannadha Sastry}, K.",
year = "2007",
month = "4",
day = "30",
doi = "10.1016/j.vaccine.2007.01.010",
language = "English (US)",
volume = "25",
pages = "3302--3310",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17",

}

TY - JOUR

T1 - Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection

AU - Manuri, Pallavi R.

AU - Nehete, Bharti

AU - Nehete, Pramod N.

AU - Reisenauer, Rose

AU - Wardell, Seth

AU - Courtney, Amy N.

AU - Gambhira, Ratish

AU - Lomada, Dakshyani

AU - Chopra, Ashok

AU - Jagannadha Sastry, K.

PY - 2007/4/30

Y1 - 2007/4/30

N2 - The E6 and E7 oncoproteins of the high-risk HPV type16 represent ideal targets for HPV vaccine development, they being consistently expressed in cervical cancer lesions. Since HPV-16 is primarily transmitted through genital mucosal route, mucosal immune responses constitute an essential feature for vaccination strategies against HPV-associated lesions. We present here evidence showing that mucosal immunization of mice by the intranasal route with a mixture of peptides E744-62 and E643-57 from the E7 and E6 oncoproteins of HPV-16, respectively, using a mutant cholera toxin adjuvant (CT-2*), primed strong antigen-specific cellular immune responses in systemic and mucosal tissues. Significant levels of IFN-γ production by both CD4 and CD8 cells were observed along with CTL responses that were effective against both peptide-pulsed targets as well as syngeneic tumor cells (TC-1) expressing the cognate E6 and E7 proteins. Furthermore, mice immunized with the peptide mixture and CT-2* effectively resisted TC-1 tumor challenge. These results together with our earlier observations that T cell responses to these peptides correlate with recurrence-free survival in women after ablative treatment for HPV-associated cervical intraepithelial neoplasia, support the potential of these E6 and E7 peptides for inclusion in vaccine formulations.

AB - The E6 and E7 oncoproteins of the high-risk HPV type16 represent ideal targets for HPV vaccine development, they being consistently expressed in cervical cancer lesions. Since HPV-16 is primarily transmitted through genital mucosal route, mucosal immune responses constitute an essential feature for vaccination strategies against HPV-associated lesions. We present here evidence showing that mucosal immunization of mice by the intranasal route with a mixture of peptides E744-62 and E643-57 from the E7 and E6 oncoproteins of HPV-16, respectively, using a mutant cholera toxin adjuvant (CT-2*), primed strong antigen-specific cellular immune responses in systemic and mucosal tissues. Significant levels of IFN-γ production by both CD4 and CD8 cells were observed along with CTL responses that were effective against both peptide-pulsed targets as well as syngeneic tumor cells (TC-1) expressing the cognate E6 and E7 proteins. Furthermore, mice immunized with the peptide mixture and CT-2* effectively resisted TC-1 tumor challenge. These results together with our earlier observations that T cell responses to these peptides correlate with recurrence-free survival in women after ablative treatment for HPV-associated cervical intraepithelial neoplasia, support the potential of these E6 and E7 peptides for inclusion in vaccine formulations.

KW - HPV16 E7 and E6 peptides

KW - Mucosal immunization

KW - Mutant cholera toxin

UR - http://www.scopus.com/inward/record.url?scp=34047177051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047177051&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.01.010

DO - 10.1016/j.vaccine.2007.01.010

M3 - Article

C2 - 17291642

AN - SCOPUS:34047177051

VL - 25

SP - 3302

EP - 3310

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17

ER -